Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,068 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z, Yan X, Tang P, Tang T, Wang Y, Peng S, Wang S, Lan W, Wang L, Zhang Y, Zhang J, Li K, Shu Z, Xu J, Qin J, Zhang D, Jiang J, Liu Q. Wang Z, et al. Among authors: tang t, tang p. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):180-187. doi: 10.1038/s41391-022-00618-2. Epub 2022 Nov 18. Prostate Cancer Prostatic Dis. 2023. PMID: 36401126
Genotype-phenotype correlation in patients with 21-hydroxylase deficiency.
Tang P, Zhang J, Peng S, Wang Y, Li H, Wang Z, Zhang Y, Huang Y, Xu J, Zhang D, Liu Q, Wang L, Lan W, Jiang J. Tang P, et al. Front Endocrinol (Lausanne). 2023 Mar 13;14:1095719. doi: 10.3389/fendo.2023.1095719. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36992809 Free PMC article.
PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma.
Peng S, Wang Z, Tang P, Wang S, Huang Y, Xie Q, Wang Y, Tan X, Tang T, Yan X, Xu J, Lan W, Wang L, Zhang D, Wang B, Pan T, Qin J, Jiang J, Liu Q. Peng S, et al. Among authors: tang t, tang p. Sci Adv. 2023 Aug 2;9(31):eadf3566. doi: 10.1126/sciadv.adf3566. Epub 2023 Aug 2. Sci Adv. 2023. PMID: 37531433 Free PMC article.
Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
Liang Y, Liu J, Ge J, Shi Q, Zhang G, Wan A, Luo T, Tian H, Fan L, Wang S, Chen L, Tang P, Zhu K, Jiang J, Bian X, Zhang Y, Qi X. Liang Y, et al. Among authors: tang p. EClinicalMedicine. 2024 Apr 11;71:102585. doi: 10.1016/j.eclinm.2024.102585. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38638401 Free PMC article.
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q, Xuhong J, Luo T, Ge J, Liu F, Lan Y, Chen Q, Tang P, Fan L, Chen L, Liang Y, Wang M, Hu Y, Zhang Y, Bian X, Qi X, Jiang J. Shi Q, et al. Among authors: tang p. Br J Cancer. 2023 Jan;128(1):121-129. doi: 10.1038/s41416-022-02021-z. Epub 2022 Nov 2. Br J Cancer. 2023. PMID: 36323880 Free PMC article.
4,068 results